SCHEDULE: Lynx1 Capital Boosts Stake in Passage BIO to 19.6%

Lynx1 Capital Management LP and Weston Nichols have disclosed a significant beneficial ownership stake of 19.6% in Passage BIO, Inc., holding 623,704 shares.

Summary

• Lynx1 Capital Management LP and Weston Nichols collectively reported beneficial ownership of 623,704 shares of Passage BIO, Inc. Common Stock.
• This ownership represents 19.6% of the company's outstanding Common Stock.
• The percentage is calculated based on 3,178,710 shares outstanding as of August 7, 2025, as reported in Passage BIO's Form 10-Q for the quarter ended June 30, 2025.
• Both Lynx1 Capital Management LP and Weston Nichols hold shared voting power and shared dispositive power over all 623,704 shares.
• The securities were not acquired or held for the purpose of changing or influencing the control of Passage BIO, Inc., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by an investment manager is generally viewed positively, indicating institutional confidence in the company. While it doesn't provide operational details, it suggests a belief in the company's value proposition.

Positives

• A significant stake of 19.6% by an investment manager and its principal may signal confidence in Passage BIO's future prospects.
• The disclosure of a substantial institutional holding can attract attention from other investors and potentially stabilize the stock.

Negatives

• The filing itself does not contain information that would be considered negative regarding the company's operational or financial performance.

Risks

• The concentration of a significant portion of voting and dispositive power (19.6%) with a single investment group could influence corporate decisions, potentially aligning with the interests of the reporting persons rather than all shareholders.
• While the reporting persons certify they are not seeking to influence control, a large stake always carries the inherent risk of future activist engagement or changes in investment strategy that could impact the company.

Management Comments

• Weston Nichols, on behalf of Lynx1 Capital Management LP and individually, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Passage BIO, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by a capital management firm in a biotechnology company, which is a common occurrence in the sector as institutional investors seek opportunities in high-growth, innovation-driven industries like gene therapy. The size of the stake suggests a long-term interest or a strategic position within the company's equity structure.

Stakeholder Impact

• Shareholders: The significant stake by Lynx1 Capital Management LP and Weston Nichols could be seen as a vote of confidence, potentially influencing market perception and share price stability. It also means a large block of shares is controlled by a single entity, which could impact future voting outcomes.
• Management: The presence of a large institutional investor may lead to increased scrutiny or engagement regarding strategic decisions and corporate performance.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant beneficial ownership stake by Lynx1 Capital Management LP and Weston Nichols in Passage BIO, Inc. While a large institutional investment can be a positive signal of confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily discloses ownership structure. Investors should 'hold' and await further operational updates or financial reports from Passage BIO to make a more informed decision, while acknowledging the potential positive sentiment from this institutional backing.

Keywords

Passage BIO, Lynx1 Capital Management, Weston Nichols, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Gene Therapy